Kohzo Takebayashi, Toshihiko Inukai. J Clin Med Res 2017
Times Cited: 17
Times Cited: 17
Times Cited
Times Co-cited
Similarity
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
52
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
41
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
35
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
35
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
29
Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans.
Muhammad A Abdul-Ghani, Ralph A DeFronzo, Luke Norton. Diabetes 2013
Muhammad A Abdul-Ghani, Ralph A DeFronzo, Luke Norton. Diabetes 2013
29
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
23
LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
David R Powell, Melinda Smith, Jennifer Greer, Angela Harris, Sharon Zhao, Christopher DaCosta, Faika Mseeh, Melanie K Shadoan, Arthur Sands, Brian Zambrowicz,[...]. J Pharmacol Exp Ther 2013
David R Powell, Melinda Smith, Jennifer Greer, Angela Harris, Sharon Zhao, Christopher DaCosta, Faika Mseeh, Melanie K Shadoan, Arthur Sands, Brian Zambrowicz,[...]. J Pharmacol Exp Ther 2013
23
Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
23
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
17
Chylomicrons stimulate incretin secretion in mouse and human cells.
Arianna Psichas, Pierre F Larraufie, Deborah A Goldspink, Fiona M Gribble, Frank Reimann. Diabetologia 2017
Arianna Psichas, Pierre F Larraufie, Deborah A Goldspink, Fiona M Gribble, Frank Reimann. Diabetologia 2017
17
Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine.
Louise W Christensen, Rune E Kuhre, Charlotte Janus, Berit Svendsen, Jens J Holst. Physiol Rep 2015
Louise W Christensen, Rune E Kuhre, Charlotte Janus, Berit Svendsen, Jens J Holst. Physiol Rep 2015
17
Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors.
Cheryl A Brighton, Juraj Rievaj, Rune E Kuhre, Leslie L Glass, Kristina Schoonjans, Jens J Holst, Fiona M Gribble, Frank Reimann. Endocrinology 2015
Cheryl A Brighton, Juraj Rievaj, Rune E Kuhre, Leslie L Glass, Kristina Schoonjans, Jens J Holst, Fiona M Gribble, Frank Reimann. Endocrinology 2015
17
Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium.
Fiona M Gribble, Frank Reimann. Annu Rev Physiol 2016
Fiona M Gribble, Frank Reimann. Annu Rev Physiol 2016
17
Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP.
Wendell J Lu, Qing Yang, Li Yang, Dana Lee, David D'Alessio, Patrick Tso. Lipids 2012
Wendell J Lu, Qing Yang, Li Yang, Dana Lee, David D'Alessio, Patrick Tso. Lipids 2012
17
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
Timo Rieg, Takahiro Masuda, Maria Gerasimova, Eric Mayoux, Kenneth Platt, David R Powell, Scott C Thomson, Hermann Koepsell, Volker Vallon. Am J Physiol Renal Physiol 2014
Timo Rieg, Takahiro Masuda, Maria Gerasimova, Eric Mayoux, Kenneth Platt, David R Powell, Scott C Thomson, Hermann Koepsell, Volker Vallon. Am J Physiol Renal Physiol 2014
17
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, Rajiv Agarwal, George L Bakris, Barry M Brenner, Scott Bull, Christopher P Cannon, David M Charytan, Dick de Zeeuw,[...]. Am J Nephrol 2017
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, Rajiv Agarwal, George L Bakris, Barry M Brenner, Scott Bull, Christopher P Cannon, David M Charytan, Dick de Zeeuw,[...]. Am J Nephrol 2017
17
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
17
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li,[...]. Circulation 2018
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li,[...]. Circulation 2018
17
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
17
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
17
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink. Diabetes Obes Metab 2018
Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink. Diabetes Obes Metab 2018
17
Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects.
M J Perley, D M Kipnis. J Clin Invest 1967
M J Perley, D M Kipnis. J Clin Invest 1967
17
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
17
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.
Julio Rosenstock, Ele Ferrannini. Diabetes Care 2015
Julio Rosenstock, Ele Ferrannini. Diabetes Care 2015
11
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
Sven Kohler, Cordula Zeller, Hristo Iliev, Stefan Kaspers. Adv Ther 2017
Sven Kohler, Cordula Zeller, Hristo Iliev, Stefan Kaspers. Adv Ther 2017
11
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
11
Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.
Tomohide Hayami, Yoshiro Kato, Hideki Kamiya, Masaki Kondo, Ena Naito, Yukako Sugiura, Chika Kojima, Sami Sato, Yuichiro Yamada, Rina Kasagi,[...]. J Diabetes Investig 2015
Tomohide Hayami, Yoshiro Kato, Hideki Kamiya, Masaki Kondo, Ena Naito, Yukako Sugiura, Chika Kojima, Sami Sato, Yuichiro Yamada, Rina Kasagi,[...]. J Diabetes Investig 2015
11
The incretin system and its role in type 2 diabetes mellitus.
Jens Juul Holst, Tina Vilsbøll, Carolyn F Deacon. Mol Cell Endocrinol 2009
Jens Juul Holst, Tina Vilsbøll, Carolyn F Deacon. Mol Cell Endocrinol 2009
11
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. Biopharm Drug Dispos 2014
Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. Biopharm Drug Dispos 2014
11
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
11
Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers.
T E Adrian, S Gariballa, K A Parekh, S A Thomas, H Saadi, J Al Kaabi, N Nagelkerke, B Gedulin, A A Young. Diabetologia 2012
T E Adrian, S Gariballa, K A Parekh, S A Thomas, H Saadi, J Al Kaabi, N Nagelkerke, B Gedulin, A A Young. Diabetologia 2012
11
Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
Mark Ellrichmann, Mario Kapelle, Peter R Ritter, Jens J Holst, Karl-Heinz Herzig, Wolfgang E Schmidt, Frank Schmitz, Juris J Meier. J Clin Endocrinol Metab 2008
Mark Ellrichmann, Mario Kapelle, Peter R Ritter, Jens J Holst, Karl-Heinz Herzig, Wolfgang E Schmidt, Frank Schmitz, Juris J Meier. J Clin Endocrinol Metab 2008
11
Metformin and the gastrointestinal tract.
Laura J McCreight, Clifford J Bailey, Ewan R Pearson. Diabetologia 2016
Laura J McCreight, Clifford J Bailey, Ewan R Pearson. Diabetologia 2016
11
Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
J N Roberge, P L Brubaker. Endocrinology 1993
J N Roberge, P L Brubaker. Endocrinology 1993
11
Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.
Gwen Tolhurst, Helen Heffron, Yu Shan Lam, Helen E Parker, Abdella M Habib, Eleftheria Diakogiannaki, Jennifer Cameron, Johannes Grosse, Frank Reimann, Fiona M Gribble. Diabetes 2012
Gwen Tolhurst, Helen Heffron, Yu Shan Lam, Helen E Parker, Abdella M Habib, Eleftheria Diakogiannaki, Jennifer Cameron, Johannes Grosse, Frank Reimann, Fiona M Gribble. Diabetes 2012
11
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
M S Svane, N B Jørgensen, K N Bojsen-Møller, C Dirksen, S Nielsen, V B Kristiansen, S Toräng, N J Wewer Albrechtsen, J F Rehfeld, B Hartmann,[...]. Int J Obes (Lond) 2016
M S Svane, N B Jørgensen, K N Bojsen-Møller, C Dirksen, S Nielsen, V B Kristiansen, S Toräng, N J Wewer Albrechtsen, J F Rehfeld, B Hartmann,[...]. Int J Obes (Lond) 2016
11
alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
K Hücking, Z Kostic, C Pox, R Ritzel, J J Holst, W Schmiegel, M A Nauck. Diabet Med 2005
K Hücking, Z Kostic, C Pox, R Ritzel, J J Holst, W Schmiegel, M A Nauck. Diabet Med 2005
11
Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion.
A S Rocca, P L Brubaker. Endocrinology 1999
A S Rocca, P L Brubaker. Endocrinology 1999
11
Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution.
Filip K Knop, Tina Vilsbøll, Steen Larsen, Patricia V Højberg, Aage Vølund, Sten Madsbad, Jens J Holst, Thure Krarup. Am J Physiol Endocrinol Metab 2007
Filip K Knop, Tina Vilsbøll, Steen Larsen, Patricia V Højberg, Aage Vølund, Sten Madsbad, Jens J Holst, Thure Krarup. Am J Physiol Endocrinol Metab 2007
11
Gut Hormone Regulation and Secretion via FFA1 and FFA4.
Fiona M Gribble, Eleftheria Diakogiannaki, Frank Reimann. Handb Exp Pharmacol 2017
Fiona M Gribble, Eleftheria Diakogiannaki, Frank Reimann. Handb Exp Pharmacol 2017
11
Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.
Nils B Jørgensen, Carsten Dirksen, Kirstine N Bojsen-Møller, Siv H Jacobsen, Dorte Worm, Dorte L Hansen, Viggo B Kristiansen, Lars Naver, Sten Madsbad, Jens J Holst. Diabetes 2013
Nils B Jørgensen, Carsten Dirksen, Kirstine N Bojsen-Møller, Siv H Jacobsen, Dorte Worm, Dorte L Hansen, Viggo B Kristiansen, Lars Naver, Sten Madsbad, Jens J Holst. Diabetes 2013
11
Signalling pathways involved in the detection of peptones by murine small intestinal enteroendocrine L-cells.
Ramona Pais, Fiona M Gribble, Frank Reimann. Peptides 2016
Ramona Pais, Fiona M Gribble, Frank Reimann. Peptides 2016
11
Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
11
Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
M Hansen, M J Scheltema, D P Sonne, J S Hansen, M Sperling, J F Rehfeld, J J Holst, T Vilsbøll, F K Knop. Diabetes Obes Metab 2016
M Hansen, M J Scheltema, D P Sonne, J S Hansen, M Sperling, J F Rehfeld, J J Holst, T Vilsbøll, F K Knop. Diabetes Obes Metab 2016
11
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
David Polidori, Sue Sha, Sunder Mudaliar, Theodore P Ciaraldi, Atalanta Ghosh, Nicole Vaccaro, Kristin Farrell, Paul Rothenberg, Robert R Henry. Diabetes Care 2013
David Polidori, Sue Sha, Sunder Mudaliar, Theodore P Ciaraldi, Atalanta Ghosh, Nicole Vaccaro, Kristin Farrell, Paul Rothenberg, Robert R Henry. Diabetes Care 2013
11
Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans.
T Wu, M J Bound, S D Standfield, B Gedulin, K L Jones, M Horowitz, C K Rayner. Diabetes Obes Metab 2013
T Wu, M J Bound, S D Standfield, B Gedulin, K L Jones, M Horowitz, C K Rayner. Diabetes Obes Metab 2013
11
Generation of L cells in mouse and human small intestine organoids.
Natalia Petersen, Frank Reimann, Sina Bartfeld, Henner F Farin, Femke C Ringnalda, Robert G J Vries, Stieneke van den Brink, Hans Clevers, Fiona M Gribble, Eelco J P de Koning. Diabetes 2014
Natalia Petersen, Frank Reimann, Sina Bartfeld, Henner F Farin, Femke C Ringnalda, Robert G J Vries, Stieneke van den Brink, Hans Clevers, Fiona M Gribble, Eelco J P de Koning. Diabetes 2014
11
Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose).
C Qualmann, M A Nauck, J J Holst, C Orskov, W Creutzfeldt. Scand J Gastroenterol 1995
C Qualmann, M A Nauck, J J Holst, C Orskov, W Creutzfeldt. Scand J Gastroenterol 1995
11
Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
Jerry R Greenfield, I Sadaf Farooqi, Julia M Keogh, Elana Henning, Abdella M Habib, Anthea Blackwood, Frank Reimann, Jens J Holst, Fiona M Gribble. Am J Clin Nutr 2009
Jerry R Greenfield, I Sadaf Farooqi, Julia M Keogh, Elana Henning, Abdella M Habib, Anthea Blackwood, Frank Reimann, Jens J Holst, Fiona M Gribble. Am J Clin Nutr 2009
11
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.